| Market Cap | 5.28M | P/E | - | EPS this Y | 91.30% | Ern Qtrly Grth | - |
| Income | -6.53M | Forward P/E | -1.20 | EPS next Y | 109.90% | 50D Avg Chg | -5.00% |
| Sales | 7.53M | PEG | -0.05 | EPS past 5Y | - | 200D Avg Chg | -30.00% |
| Dividend | N/A | Price/Book | 2.48 | EPS next 5Y | 40.00% | 52W High Chg | -73.00% |
| Recommedations | 2.00 | Quick Ratio | 1.18 | Shares Outstanding | 819.27K | 52W Low Chg | 15.00% |
| Insider Own | 9.27% | ROA | -36.80% | Shares Float | 402.70K | Beta | 0.38 |
| Inst Own | 35.74% | ROE | -407.60% | Shares Shorted/Prior | 65.62K/3.38K | Price | 1.58 |
| Gross Margin | 96.97% | Profit Margin | -86.75% | Avg. Volume | 26,391 | Target Price | 18.00 |
| Oper. Margin | -47.96% | Earnings Date | Nov 7 | Volume | 8,683 | Change | 0.00% |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
